Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Molecular features of medulloblastoma may help personalize radiotherapy
Key clinical point: Outcomes with different radiation-reducing strategies for average-risk medulloblastoma varied by tumor molecular subgroup.
Major finding: Event-free survival was significantly poorer with whole posterior fossa radiation vs. tumor-bed radiation only in the SHH subgroup (P = .018) and with low-dose vs. standard-dose craniospinal irradiation in the group 4 subgroup (P = .047). Event-free survival did not differ significantly by boost volume or craniospinal irradiation dose in the other subgroups.
Study details: Phase 3 trial of 464 patients with average-risk medulloblastoma, including 362 patients who could be classified into molecular subgroups (SHH, WNT, group 3, and group 4).
Disclosures: The trial was funded by the National Cancer Institute, The Brain Tumor Charity, and St. Jude Children’s Research Hospital. Dr. Michalski disclosed relationships with ViewRay, Boston Scientific, Merck, and Blue Earth Diagnostics.
Michalski JM et al. ASTRO 2020, Abstract 1.